Leukemia can cause kidney problems through several different pathways, including direct invasion of the kidneys by cancer cells, metabolic disruptions from rapid cell breakdown, immune-related kidney damage, and side effects of treatment. Kidney injury affects a significant number of leukemia patients. In one study of older adults with acute leukemia undergoing stem cell transplant, nearly 55% developed some degree of acute kidney injury during treatment.
How Leukemia Cells Directly Damage the Kidneys
Leukemia cells can physically infiltrate kidney tissue. Autopsy studies of patients with chronic lymphocytic leukemia (CLL) show that 63% to 90% had leukemic cells in their kidneys at the time of death. That number sounds alarming, but here’s the important nuance: most of those patients never developed kidney failure from it. The infiltration is common, but it rarely causes enough damage on its own to shut down kidney function.
When it does cause problems, the leukemia cells crowd into the kidney’s filtering tissue in either a patchy or widespread pattern. This can compress the tiny tubes that carry urine through the kidney, blocking flow and reducing blood supply to surrounding tissue. The kidneys may become enlarged, and small amounts of protein can start leaking into the urine. In a large review of 700 patients with lymphoma and CLL, only 3 out of 17 patients with kidney involvement had damage directly caused by the leukemia itself rather than other factors.
Tumor Lysis Syndrome
One of the more serious kidney threats comes not from the leukemia growing, but from the leukemia dying. When chemotherapy kills a large number of cancer cells quickly, all their internal contents spill into the bloodstream at once. This is called tumor lysis syndrome, and it creates a metabolic emergency. Uric acid levels spike as the body tries to break down the flood of genetic material from dead cells. Phosphorus levels rise sharply too, pulling calcium out of the blood.
Both the uric acid and phosphorus can form crystals inside the kidney’s tiny filtering tubes, physically clogging them. The result is a sudden drop in kidney function that can progress to kidney failure requiring emergency treatment. Leukemias with very high white blood cell counts or rapidly dividing cells are at greatest risk, and oncology teams typically start preventive measures like aggressive hydration and uric acid-lowering medications before chemotherapy begins.
Immune-Related Kidney Disease in CLL
Chronic lymphocytic leukemia has a unique relationship with the kidneys that goes beyond direct infiltration. The cancerous B cells in CLL produce abnormal proteins that can trigger immune reactions in the kidney’s filtering units (the glomeruli). More than 50 cases of CLL-related glomerular disease have been documented in medical literature, and the pattern is distinctive.
The most common type is a condition called membranoproliferative glomerulonephritis, accounting for about 36% of reported cases. Membranous nephropathy makes up another 19%. In some patients, the abnormal proteins produced by leukemia cells fold into insoluble fibers called amyloid that deposit in kidney tissue. A Mayo Clinic review spanning 20 years identified 33 CLL patients who developed amyloidosis, with 61% caused by these abnormal light chain proteins. These glomerular diseases typically show up as protein in the urine, swelling in the legs, or gradually worsening kidney function, and treating the underlying CLL is often the most effective way to slow or reverse the kidney damage.
Chemotherapy and Kidney Toxicity
Many drugs used to treat leukemia are hard on the kidneys. The mechanisms vary by drug class, but the end result is similar: reduced filtering capacity, damage to the tubes that process urine, or injury to the blood vessels inside the kidneys.
- Platinum-based drugs like cisplatin cause direct cell death in kidney tubules and trigger inflammation and oxidative stress that reduces the kidney’s filtering rate.
- High-dose methotrexate can form crystals in the kidney’s drainage system, physically blocking urine flow and causing sudden kidney injury.
- Alkylating agents like ifosfamide and cyclophosphamide damage the kidney’s proximal tubules through toxic byproducts. Ifosfamide in particular can cause a condition where the kidneys leak essential minerals like phosphorus, sodium, and potassium into the urine.
- Certain antibiotics used in chemotherapy like doxorubicin can injure the kidney’s filtering cells, causing them to die off.
Not every leukemia patient receives these specific drugs, and oncologists weigh kidney risk when choosing a treatment plan. Hydration protocols and dose adjustments are standard strategies for reducing kidney damage during treatment.
How Kidney Problems Affect Survival
Kidney injury during leukemia treatment is not just an inconvenience. It can change the trajectory of the disease. In a study of older leukemia patients undergoing stem cell transplant, the severity of kidney injury directly correlated with survival. Patients with mild or no kidney injury had three-year survival rates around 74% to 76%. Those with moderate kidney injury dropped to about 57%, and patients with severe kidney injury had a three-year survival of just 14%.
Transplant-related mortality tells a similar story. Patients with moderate to severe kidney injury had a 48% chance of dying from transplant complications within three years, compared to roughly 14% for those with mild or no kidney problems. Moderate or severe kidney injury was independently linked to higher mortality, meaning it worsened outcomes even after accounting for other risk factors.
Long-Term Kidney Risk After Stem Cell Transplant
Even after successful treatment, the kidneys may not be out of the woods. Between 17% and 35% of stem cell transplant survivors develop chronic kidney disease during follow-up. In one cohort study of 197 patients, 11.7% developed chronic kidney disease, with a typical onset around 6 months after transplant. At five years post-transplant, about 86% of patients remained free of chronic kidney disease.
The risk factors are straightforward: older age and longer duration of the blood cancer before transplant both increase the likelihood of kidney problems. Each additional year of age raises the risk by about 8%. End-stage kidney disease requiring dialysis is roughly 20 times more common in transplant survivors than in the general population, which is why specialists recommend checking kidney function every three months for the first two years after transplant and every six months after that. Monitoring blood pressure, kidney filtering rates, and urine protein levels helps catch early problems before they become irreversible.
Signs to Watch For
Kidney problems in leukemia don’t always announce themselves loudly. Early signs can be subtle: swelling in the ankles, feet, or around the eyes, foamy urine (a sign of protein leaking into it), decreased urine output, or unexplained fatigue beyond what the leukemia itself causes. Some patients notice nausea, confusion, or muscle cramps from electrolyte imbalances. During treatment, blood work will typically catch rising creatinine levels or electrolyte shifts before symptoms appear, which is one reason frequent lab monitoring matters so much during and after leukemia therapy.